Liquidia Corporation
LQDA
Rankning i aktier
#4354
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Aktiekurs
$39.03
Marknadsvärde
$3.49B
Förändring (1 dag)
0.44%
Förändring (1 år)
74.71%
Land
US
Handel Liquidia Corporation (LQDA)
Kategori
Healthcare
Aktiekurshistorik för Liquidia Corporation (LQDA)
Högsta slutkurs: $31.14 den 2026-10-01
Lägsta slutkurs: $11.01 den 2018-07-01
Lägsta slutkurs: $11.01 den 2018-07-01
Aktiekurshistorik för Liquidia Corporation från 2018 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | 42.87% |
| 2025 | 204.28% |
| 2024 | 26.82% |
| 2023 | 47.93% |
| 2022 | 37.03% |
| 2021 | 48.32% |
| 2020 | -24.23% |
| 2019 | -82.68% |
| 2018 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $63.01 | 71.04% |
US
|
|
| $45.98 | 36.92% |
SE
|
|
| $172.16 | 24.48% |
FR
|
|
| $59.52 | -0.48% |
IT
|
|
| $108.40 | 47.18% |
US
|
